The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab.
Isabelle Fleury
No relevant relationships to disclose
Sylvie Chevret
No relevant relationships to disclose
Sandy Amorim
No relevant relationships to disclose
Emanuele Zucca
Consultant or Advisory Role - Celgene; Janssen; Roche
Michael Herold
Consultant or Advisory Role - Roche
Honoraria - Celgene; Mundipharma; Novartis; Roche
Research Funding - Roche
Michele Ghielmini
Honoraria - Genentech; Roche
Pauline Brice
Honoraria - Roche
Research Funding - Roche
Bertrand Coiffier
Consultant or Advisory Role - Roche
Gilles A. Salles
Consultant or Advisory Role - Roche
Research Funding - Roche
Catherine Thieblemont
No relevant relationships to disclose